The Journal of Nutrition Health and Aging

, Volume 12, Supplement 1, pp S61–S65

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment

  • J. R. Barrio
  • V. Kepe
  • N. Satyamurthy
  • S. C. Huang
  • G. Small


Objectives: Establish new approaches for early diagnosis of dementia, based on imaging amyloid and tau pathology, cell losses and neuronal function, in subjects with mild cognitive impairment (MCI),. The overall aim is to develop effective tools for monitoring disease progression in the living patient to facilitate discovery of early therapeutic interventions to modify the course of the disease.Design: Use 2-(l-(6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([F-18]FDDNP) in combination with positron emission tomography (PET) to produce dynamic images for quantification of regional cortical brain deposition in MCI patients and compare them with controls subjects and patients with Alzheimer’s disease (AD). Comparison with other molecular imaging probes for neuronal losses and function were also made.Setting: Patients are positioned supine in the tomograph bed with his/her head in the detector ring field. Upon injection of the molecular imaging probe (e.g., [F-18]FDDNP) images are obtained at very short time intervals for up to two hours. This results in dynamic sequences of brain distribution of the probe.Participants: Patients with clinical diagnosis of AD, MCI and control subjects.Measurements: Subjects in the categories established above were scanned with [F-18]FDDNP-PET and quantification performed using Logan parametric graphical analysis to measure relative quantitative amyloid loads throughout the brain within patient groups. These results were compared in the same patients with cell losses in hippocampus using 4-[F-18]fluoro-N-(2-[4-(2-methoxyphenyl)-l-piperazinyl]ethyl)-N-(2-pyridinyl)benzamide,([F-18]MPPF) and regional cerebral glucose metabolic rates using 2-deoxy-2-[F-18]fluoro-2-deoxy-D-glucose (2-[F-18]FDG).Results: [F-18]FDDNP reliably follows neuropathological progression (amyloid plaques [SP]; neurofibrillary tangles [NFT]) in the living brain of AD patients and those with MCI. The distribution of [F-18]FDDNP brain cortical accumulation correlates well with behavioral measures (e.g., MMSE scores) and follows known patterns of pathological distribution observed at autopsy. We have also established conversion of controls to MCI and MCI to AD with precision and sensitivity in patients and control subjects in follow-up studies. Moreover, we have established that hemispheric cortical surface mapping of [F-18]FDDNP binding is a powerful tool for assessment and visualization of the rate of brain pathology deposition. A strong correlation of [F-18]FDDNP binding, cell losses in hippocampus and decreased glucose utilization ([F-18]FDG PET) in several neocortical regions was found in the same AD and MCI subjects. Conclusions: The combined evaluation of [F-18]FDDNP PET (targeting NFT and_SP) with neuronal losses in the hippocampus and with [F-18]FDG PET (targeting neuronal function) offers the opportunity for reliable, noninvasive detection of MCI patients at risk for AD. The approach offers a glimpse to the molecular and cellular mechanisms associated with dementia and provides a means for their assessment in the living patient. Monitoring disease progression in MCI patients demonstrates the usefulness of this imaging approach for early diagnosis and provides a means for evaluation of neuroprotective agents and drugs aimed at prevention and modification of disease progression.

Key words

Mild cognitive impairment amyloid deposition neuronal losses FDDNP positron emission tomography 


  1. 1.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239–259.CrossRefGoogle Scholar
  2. 2.
    Barrio JR, Huang S-C, Cole G, Satyamurthy N, Petric A, Phelps ME, Small G (1999) PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Labelled Compd Radiopharm 42 Suppl 1: S194-S195.Google Scholar
  3. 3.
    Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC., Petric A, Satyamurthy N, Barrio JR (2003) 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer’s disease. Mol Imaging Biol 5: 404–417.PubMedCrossRefGoogle Scholar
  4. 4.
    Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24–35.PubMedCrossRefGoogle Scholar
  5. 5.
    Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652–2663.PubMedCrossRefGoogle Scholar
  6. 6.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55: 306–319.PubMedCrossRefGoogle Scholar
  7. 7.
    Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12: 584–595.PubMedCrossRefGoogle Scholar
  8. 8.
    Selkoe DJ (2001) Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimer’s Dis 3: 75–80.Google Scholar
  9. 9.
    Castellani RJ, Lee HG, Perry G, Smith MA (2006) Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen 21: 126–130.PubMedCrossRefGoogle Scholar
  10. 10.
    Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16: 4491–4500.PubMedGoogle Scholar
  11. 11.
    Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, Fletcher A, Cliffe IA, Barf T, Wikstrom H, Sedvall G (1997) Autoradiographic localization of 5-HT1A receptors in the postmortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res. 745: 96–108PubMedCrossRefGoogle Scholar
  12. 12.
    Kepe V, Barrio JR, Huang S-C, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GWW, Phelps M (2006) Serotonin 1A receptors in the living brain of Alzheimer’s disease. Proc Natl Acad Sci USA 103: 702–707PubMedCrossRefGoogle Scholar
  13. 13.
    Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334: 752–758.PubMedCrossRefGoogle Scholar
  14. 14.
    Liu J, Kepe V, Zabjek A, Petric A, Padgett HC, Satyamurthy N, Barrio JR (2007) High-yield, automated radiosynthesis of 2-(l-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration. Mol Imaging Biol 9: 6–16PubMedCrossRefGoogle Scholar
  15. 15.
    Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Brihaye C, Hassaoun W, Leviel V, Mekhsian P, Weissmann D, Pujol JF, Luxen A, Comar D (1998) High yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoroanalog of WAY-100635. Nucl Med Biol 25: 343–350.PubMedCrossRefGoogle Scholar
  16. 16.
    Padgett HC, Schmidt DG, Luxen A, Bida GT, Satyamurthy N and Barrio, JR (1989) Computer-controlled radiochemical synthesis: a chemistry process control unit for the automated production of radiochemicals. Int J Rad Appl Instrum [A] 40: 433–445.CrossRefGoogle Scholar
  17. 17.
    Kepe V, Huang S-C, Small GW, and Barrio JR (2006) Visualizing Pathology Deposits in the Living Brain of Alzheimer’s Disease Patients, Methods Enzymol, 412: 144–160.PubMedCrossRefGoogle Scholar
  18. 18.
    Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41: 17–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Hyman BT, van Hoesen GW, Damasio AR and Barnes CL (1984) Alzheimer’s disease: Cell specific pathology isolates the hippocampal formation. Science 225: 1168–1170.PubMedCrossRefGoogle Scholar
  20. 20.
    Bobinski M, Wegiel J, Tarnawski M, Reisberg B, de Leon MJ, Miller DC, Wisniewski HM (1997) Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol 56: 414–420.PubMedCrossRefGoogle Scholar
  21. 21.
    Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB (1999) Screening for dementia with the memory impairment screen. Neurology 52: 231–238.PubMedGoogle Scholar
  22. 22.
    Minoshima S, Frey KA, Cross DJ, Kuhl DE (2004). Neurochemical imaging of dementias. Sem Nucl Med 34: 70–82.CrossRefGoogle Scholar
  23. 23.
    Protas H, S-C Huang S-C, Kepe V, Hayashi K, Klunder A, Braskie M, Ercoli L, Bookheimer S, Thompson P, Barrio J, Small G(2007). Hemispheric cortical surface map for assessing the rate of changes of regional cortical FDDNP distribution volume versus MMSE score. J Nucl Med 48 (Supplement 2): 419P.Google Scholar

Copyright information

© Springer-Verlag France and Serdi Éditions 2008

Authors and Affiliations

  • J. R. Barrio
    • 1
  • V. Kepe
    • 1
  • N. Satyamurthy
    • 1
  • S. C. Huang
    • 1
  • G. Small
    • 2
  1. 1.Department of Molecular and Medical PharmacologyDavid Geffen UCLA School of MedicineLos Angeles
  2. 2.Semel Institute for Neuroscience and Human BehaviorDavid Geffen UCLA School of MedicineLos Angeles

Personalised recommendations